List of works - Naoya Yamazaki

Absence of toxic epidermal necrolysis recurrence with pembrolizumab re-challenge in a patient with a positive lymphocyte transformation test

scientific article published on 20 August 2020

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

scientific article published on 22 October 2019

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

article

Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report

scientific article published on 31 October 2019

Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer

scientific article published on 02 December 2020

Case of multiple ectopic extramammary Paget's disease of the trunk

scientific article published on 06 July 2020

Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study

scientific article published on 11 March 2020

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.

scientific article

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study

scientific article

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma

scientific article published on 18 August 2020

Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor

scientific article published on 29 August 2020

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab

scientific article published on 31 October 2018

Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review

scientific article published on 19 March 2020

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption

scientific article published on 07 November 2018

Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab

scientific article published on 04 April 2019

Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma

scientific article published on 17 September 2019

Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

scientific article published on 23 May 2019

Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: A single-institution study

scientific article published on 10 March 2020

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

scientific article

Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma

scientific article published on 26 December 2019

Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma

scientific article published on 28 July 2020

Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance

scientific article published on 08 June 2020

Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance.

scientific article published on 20 February 2018

Secretory carcinoma of the skin arising on the eyelid, distinguished by immunohistochemical markers and fluorescence in situ hybridization

scientific article published on 06 January 2020

Survivin: A novel marker and potential therapeutic target for human angiosarcoma.

scientific article published on 28 August 2017

List of works by Naoya Yamazaki

Absence of toxic epidermal necrolysis recurrence with pembrolizumab re-challenge in a patient with a positive lymphocyte transformation test

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report

Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer

Case of multiple ectopic extramammary Paget's disease of the trunk

Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma

Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab

Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption

Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab

Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma

Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: A single-institution study

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma

Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma

Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance

Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance.

Secretory carcinoma of the skin arising on the eyelid, distinguished by immunohistochemical markers and fluorescence in situ hybridization

Survivin: A novel marker and potential therapeutic target for human angiosarcoma.